Pharma News
Relyvrio Falls Short of Primary Endpoint in Phase III PHOENIX Trial in Patients with ALS
![](https://meefro.com/wp-content/uploads/2024/03/Relyvrio-Falls-Short-of-Primary-Endpoint-in-Phase-III-PHOENIX-780x470.png)
Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48 compared to placebo.
Source link
#Relyvrio #Falls #Short #Primary #Endpoint #Phase #III #PHOENIX #Trial #Patients #ALS